Alfonso Quintás‐Cardama

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results”.

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

Nature Medicine(2023)10.1038/s41591-023-02452-y

N/A

2.2DataRank · unranked

106 citations

Marcus O. Butler, Roisin E. O’Cearbhaill, David Y. Oh, Melissa L. Johnson, Kevin Zikaras +10 more

A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3790

N/A

0DataRank · unranked

11 citations

Amir T. Fathi, Ashwin Kishtagari, Kapil N. Bhalla, Alfonso Quintás‐Cardama, Sarah A. Reilly +25 more